{
  "as_of": "2026-11-02",
  "track": "radiopharma",
  "source_url": "https://drugnews.com.tw/en/asia-radiopharma-leaders.html",
  "headers": [
    "rank",
    "asset",
    "inn",
    "originator",
    "country",
    "target",
    "mechanism",
    "highest_stage",
    "indications",
    "trial_ids",
    "overseas_rights_holder",
    "deal_date",
    "upfront",
    "total_value",
    "latest_event",
    "latest_event_date",
    "source_urls",
    "source_date"
  ],
  "rows": [
    [
      "1",
      "Lu-177-DGUL (pocubotide)",
      "pocubotide (per Korean press; INN spelling not confirmed on WHO list)",
      "Cellbion Co., Ltd.",
      "South Korea",
      "PSMA",
      "177Lu-labelled small-molecule PSMA radioligand (beta emitter); theranostic pair with Ga-68-NGUL",
      "Registration — South Korea (MFDS conditional approval filed 2025-12-30; under review)",
      "PSMA-positive mCRPC refractory to standard therapy; Ph3 vs SOC approved; Ph1 combo with pembrolizumab",
      "NCT05547061",
      "None reported (partnering talks reported, no signed deal)",
      "—",
      "—",
      "—",
      "MFDS approved Phase 3 IND (150 pts, 1:1 vs standard care) in mCRPC; conditional approval decision still pending",
      "2026-09-29",
      "https://clinicaltrials.gov/study/NCT05547061 | https://news.bizwatch.co.kr/article/healthcare/2026/09/29/0001 | https://en.edaily.co.kr/news/eda202607305141/",
      "2026-09-29"
    ],
    [
      "2",
      "FC705 ([177Lu]Ludotadipep)",
      "ludotadipep",
      "FutureChem Co., Ltd.",
      "South Korea",
      "PSMA",
      "177Lu-labelled small-molecule PSMA radioligand (beta emitter)",
      "Phase 3 — South Korea (2026-01)",
      "mCRPC (Ph3 Korea, rPFS by BICR); Ph2a in US",
      "NCT07853209 | NCT04509557 | NCT05579184",
      "None reported for FC705 (FutureChem's China/Europe deals cover diagnostic FC303 only)",
      "—",
      "—",
      "—",
      "Randomized Phase 3 in mCRPC (started 2026-01-26) registered on ClinicalTrials.gov",
      "2026-10-01",
      "https://clinicaltrials.gov/study/NCT07853209 | https://en.edaily.co.kr/news/eda202606125101/",
      "2026-10-01"
    ],
    [
      "3",
      "HRS-4357",
      "—",
      "Jiangsu Hengrui Pharmaceuticals",
      "China",
      "PSMA",
      "177Lu-labelled PSMA-targeted radioligand (beta emitter)",
      "Phase 3 — China (2026-02)",
      "PSMA-positive progressive mCRPC vs switch of ARPI (Ph3, n=370); advanced prostate cancer (Ph1/2)",
      "NCT07311694 | NCT06006104",
      "None reported",
      "—",
      "—",
      "—",
      "Phase 3 vs novel ARPI in PSMA-positive mCRPC started enrolling",
      "2026-02-02",
      "https://clinicaltrials.gov/study/NCT07311694 | https://clinicaltrials.gov/study/NCT06006104 | https://www.pharnexcloud.com/zixun/shiye/lcyj_89134",
      "2026-02-04"
    ],
    [
      "4",
      "177Lu-NYM032",
      "—",
      "Norroy Bioscience (Wuxi Nuoyu Pharmaceutical Technology)",
      "China",
      "PSMA",
      "177Lu-labelled small-molecule PSMA radioligand; theranostic pair with 68Ga-NYM032 (same precursor)",
      "Phase 3 — China (NMPA-cleared; registered 2026-08, not yet recruiting)",
      "Progressive PSMA-positive mCRPC vs best standard of care (Ph3, OS endpoint); mCRPC (Ph1/2)",
      "NCT07795268 | NCT06383052",
      "None reported",
      "—",
      "—",
      "—",
      "Norroy announced NMPA clearance for pivotal Phase 3 of 177Lu-NYM032 in mCRPC",
      "2026-09-02",
      "https://clinicaltrials.gov/study/NCT07795268 | https://clinicaltrials.gov/study/NCT06383052 | https://www.webull.com/news/15507958104122368 | https://www.clinicaltrialsarena.com/news/norroy-chinas-clearance-for-phase-iii-study/",
      "2026-09-03"
    ],
    [
      "5",
      "177Lu-LNC1011",
      "—",
      "Yantai Lannacheng Biotechnology (LNC; Dongcheng Pharmaceutical subsidiary)",
      "China",
      "PSMA",
      "177Lu-labelled small-molecule PSMA ligand (dansyl-modified PSMA ligand)",
      "Phase 2 — China (Ph1/2; Ph2 enrollment completed 2026-01)",
      "PSMA-positive mCRPC; Ph3 planned 1H 2027; 225Ac-LNC1011 follow-on in Ph1/2",
      "NCT06250244 (IIT) | NCT06377683 (IIT)",
      "None reported",
      "—",
      "—",
      "—",
      "LNC re-filed Hong Kong IPO application disclosing Ph2 enrollment completed (Jan 2026) and Ph3 planned for 1H 2027",
      "2026-06-12",
      "https://www1.hkexnews.hk/app/sehk/2026/108638/a134002/sehk26061202255_c.pdf | https://m.huxiu.com/article/4889966.html | https://clinicaltrials.gov/study/NCT06377683",
      "2026-09-10"
    ],
    [
      "6",
      "TRC003",
      "—",
      "C Ray Therapeutics (Chengdu) Co., Ltd.",
      "China",
      "PSMA",
      "225Ac-labelled PSMA-targeted radiopharmaceutical (alpha emitter)",
      "Phase 1/2 — China (2026-05)",
      "Progressive PSMA-positive mCRPC after ARPI or taxane (randomized 3-dose Ph1/2, n=90)",
      "NCT07567521",
      "None reported",
      "—",
      "—",
      "—",
      "Randomized Phase 1/2 in PSMA-positive mCRPC started",
      "2026-05-22",
      "https://clinicaltrials.gov/study/NCT07567521 | https://navigator.reaganudall.org/c-ray-therapeutics-chengdu-co-ltd",
      "2026-05-29"
    ],
    [
      "7",
      "PD-32766T (225Ac-PD-32766)",
      "—",
      "PeptiDream Inc.",
      "Japan",
      "CA9 (carbonic anhydrase IX)",
      "225Ac-labelled macrocyclic peptide (alpha emitter); theranostic pair with 64Cu-PD-32766D",
      "Phase 1 — US (2026-07)",
      "Relapsed/refractory CA9-positive clear cell renal cell carcinoma",
      "NCT07688187",
      "None reported (in-house PeptiDream / PDRadiopharma discovery)",
      "—",
      "—",
      "—",
      "Phase 1a/1b theranostic study (64Cu-PD-32766D imaging + 225Ac-PD-32766T therapy) started in the US",
      "2026-07-07",
      "https://clinicaltrials.gov/study/NCT07688187 | https://www.ncc.go.jp/en/information/press_release/2025/0328/index.html",
      "2026-09-18"
    ]
  ],
  "row_sources": [
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT05547061",
        "source_date": "2026-09-29"
      },
      {
        "url": "https://news.bizwatch.co.kr/article/healthcare/2026/09/29/0001",
        "source_date": "2026-09-29"
      },
      {
        "url": "https://en.edaily.co.kr/news/eda202607305141/",
        "source_date": "2026-09-29"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07853209",
        "source_date": "2026-10-01"
      },
      {
        "url": "https://en.edaily.co.kr/news/eda202606125101/",
        "source_date": "2026-10-01"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07311694",
        "source_date": "2026-02-04"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06006104",
        "source_date": "2026-02-04"
      },
      {
        "url": "https://www.pharnexcloud.com/zixun/shiye/lcyj_89134",
        "source_date": "2026-02-04"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07795268",
        "source_date": "2026-09-03"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06383052",
        "source_date": "2026-09-03"
      },
      {
        "url": "https://www.webull.com/news/15507958104122368",
        "source_date": "2026-09-03"
      },
      {
        "url": "https://www.clinicaltrialsarena.com/news/norroy-chinas-clearance-for-phase-iii-study/",
        "source_date": "2026-09-03"
      }
    ],
    [
      {
        "url": "https://www1.hkexnews.hk/app/sehk/2026/108638/a134002/sehk26061202255_c.pdf",
        "source_date": "2026-09-10"
      },
      {
        "url": "https://m.huxiu.com/article/4889966.html",
        "source_date": "2026-09-10"
      },
      {
        "url": "https://clinicaltrials.gov/study/NCT06377683",
        "source_date": "2026-09-10"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07567521",
        "source_date": "2026-05-29"
      },
      {
        "url": "https://navigator.reaganudall.org/c-ray-therapeutics-chengdu-co-ltd",
        "source_date": "2026-05-29"
      }
    ],
    [
      {
        "url": "https://clinicaltrials.gov/study/NCT07688187",
        "source_date": "2026-09-18"
      },
      {
        "url": "https://www.ncc.go.jp/en/information/press_release/2025/0328/index.html",
        "source_date": "2026-09-18"
      }
    ]
  ],
  "records": [
    {
      "rank": "1",
      "asset": "Lu-177-DGUL (pocubotide)",
      "inn": "pocubotide (per Korean press; INN spelling not confirmed on WHO list)",
      "originator": "Cellbion Co., Ltd.",
      "country": "South Korea",
      "target": "PSMA",
      "mechanism": "177Lu-labelled small-molecule PSMA radioligand (beta emitter); theranostic pair with Ga-68-NGUL",
      "highest_stage": "Registration — South Korea (MFDS conditional approval filed 2025-12-30; under review)",
      "indications": "PSMA-positive mCRPC refractory to standard therapy; Ph3 vs SOC approved; Ph1 combo with pembrolizumab",
      "trial_ids": "NCT05547061",
      "overseas_rights_holder": "None reported (partnering talks reported, no signed deal)",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "MFDS approved Phase 3 IND (150 pts, 1:1 vs standard care) in mCRPC; conditional approval decision still pending",
      "latest_event_date": "2026-09-29",
      "source_urls": "https://clinicaltrials.gov/study/NCT05547061 | https://news.bizwatch.co.kr/article/healthcare/2026/09/29/0001 | https://en.edaily.co.kr/news/eda202607305141/",
      "source_date": "2026-09-29"
    },
    {
      "rank": "2",
      "asset": "FC705 ([177Lu]Ludotadipep)",
      "inn": "ludotadipep",
      "originator": "FutureChem Co., Ltd.",
      "country": "South Korea",
      "target": "PSMA",
      "mechanism": "177Lu-labelled small-molecule PSMA radioligand (beta emitter)",
      "highest_stage": "Phase 3 — South Korea (2026-01)",
      "indications": "mCRPC (Ph3 Korea, rPFS by BICR); Ph2a in US",
      "trial_ids": "NCT07853209 | NCT04509557 | NCT05579184",
      "overseas_rights_holder": "None reported for FC705 (FutureChem's China/Europe deals cover diagnostic FC303 only)",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Randomized Phase 3 in mCRPC (started 2026-01-26) registered on ClinicalTrials.gov",
      "latest_event_date": "2026-10-01",
      "source_urls": "https://clinicaltrials.gov/study/NCT07853209 | https://en.edaily.co.kr/news/eda202606125101/",
      "source_date": "2026-10-01"
    },
    {
      "rank": "3",
      "asset": "HRS-4357",
      "inn": "—",
      "originator": "Jiangsu Hengrui Pharmaceuticals",
      "country": "China",
      "target": "PSMA",
      "mechanism": "177Lu-labelled PSMA-targeted radioligand (beta emitter)",
      "highest_stage": "Phase 3 — China (2026-02)",
      "indications": "PSMA-positive progressive mCRPC vs switch of ARPI (Ph3, n=370); advanced prostate cancer (Ph1/2)",
      "trial_ids": "NCT07311694 | NCT06006104",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Phase 3 vs novel ARPI in PSMA-positive mCRPC started enrolling",
      "latest_event_date": "2026-02-02",
      "source_urls": "https://clinicaltrials.gov/study/NCT07311694 | https://clinicaltrials.gov/study/NCT06006104 | https://www.pharnexcloud.com/zixun/shiye/lcyj_89134",
      "source_date": "2026-02-04"
    },
    {
      "rank": "4",
      "asset": "177Lu-NYM032",
      "inn": "—",
      "originator": "Norroy Bioscience (Wuxi Nuoyu Pharmaceutical Technology)",
      "country": "China",
      "target": "PSMA",
      "mechanism": "177Lu-labelled small-molecule PSMA radioligand; theranostic pair with 68Ga-NYM032 (same precursor)",
      "highest_stage": "Phase 3 — China (NMPA-cleared; registered 2026-08, not yet recruiting)",
      "indications": "Progressive PSMA-positive mCRPC vs best standard of care (Ph3, OS endpoint); mCRPC (Ph1/2)",
      "trial_ids": "NCT07795268 | NCT06383052",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Norroy announced NMPA clearance for pivotal Phase 3 of 177Lu-NYM032 in mCRPC",
      "latest_event_date": "2026-09-02",
      "source_urls": "https://clinicaltrials.gov/study/NCT07795268 | https://clinicaltrials.gov/study/NCT06383052 | https://www.webull.com/news/15507958104122368 | https://www.clinicaltrialsarena.com/news/norroy-chinas-clearance-for-phase-iii-study/",
      "source_date": "2026-09-03"
    },
    {
      "rank": "5",
      "asset": "177Lu-LNC1011",
      "inn": "—",
      "originator": "Yantai Lannacheng Biotechnology (LNC; Dongcheng Pharmaceutical subsidiary)",
      "country": "China",
      "target": "PSMA",
      "mechanism": "177Lu-labelled small-molecule PSMA ligand (dansyl-modified PSMA ligand)",
      "highest_stage": "Phase 2 — China (Ph1/2; Ph2 enrollment completed 2026-01)",
      "indications": "PSMA-positive mCRPC; Ph3 planned 1H 2027; 225Ac-LNC1011 follow-on in Ph1/2",
      "trial_ids": "NCT06250244 (IIT) | NCT06377683 (IIT)",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "LNC re-filed Hong Kong IPO application disclosing Ph2 enrollment completed (Jan 2026) and Ph3 planned for 1H 2027",
      "latest_event_date": "2026-06-12",
      "source_urls": "https://www1.hkexnews.hk/app/sehk/2026/108638/a134002/sehk26061202255_c.pdf | https://m.huxiu.com/article/4889966.html | https://clinicaltrials.gov/study/NCT06377683",
      "source_date": "2026-09-10"
    },
    {
      "rank": "6",
      "asset": "TRC003",
      "inn": "—",
      "originator": "C Ray Therapeutics (Chengdu) Co., Ltd.",
      "country": "China",
      "target": "PSMA",
      "mechanism": "225Ac-labelled PSMA-targeted radiopharmaceutical (alpha emitter)",
      "highest_stage": "Phase 1/2 — China (2026-05)",
      "indications": "Progressive PSMA-positive mCRPC after ARPI or taxane (randomized 3-dose Ph1/2, n=90)",
      "trial_ids": "NCT07567521",
      "overseas_rights_holder": "None reported",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Randomized Phase 1/2 in PSMA-positive mCRPC started",
      "latest_event_date": "2026-05-22",
      "source_urls": "https://clinicaltrials.gov/study/NCT07567521 | https://navigator.reaganudall.org/c-ray-therapeutics-chengdu-co-ltd",
      "source_date": "2026-05-29"
    },
    {
      "rank": "7",
      "asset": "PD-32766T (225Ac-PD-32766)",
      "inn": "—",
      "originator": "PeptiDream Inc.",
      "country": "Japan",
      "target": "CA9 (carbonic anhydrase IX)",
      "mechanism": "225Ac-labelled macrocyclic peptide (alpha emitter); theranostic pair with 64Cu-PD-32766D",
      "highest_stage": "Phase 1 — US (2026-07)",
      "indications": "Relapsed/refractory CA9-positive clear cell renal cell carcinoma",
      "trial_ids": "NCT07688187",
      "overseas_rights_holder": "None reported (in-house PeptiDream / PDRadiopharma discovery)",
      "deal_date": "—",
      "upfront": "—",
      "total_value": "—",
      "latest_event": "Phase 1a/1b theranostic study (64Cu-PD-32766D imaging + 225Ac-PD-32766T therapy) started in the US",
      "latest_event_date": "2026-07-07",
      "source_urls": "https://clinicaltrials.gov/study/NCT07688187 | https://www.ncc.go.jp/en/information/press_release/2025/0328/index.html",
      "source_date": "2026-09-18"
    }
  ]
}